RAGE Biotech
Christopher Wraight is an experienced executive in the biotechnology and pharmaceutical sectors, currently serving as the Chief Scientific Officer, Board Director, and Founding CEO of RAGE Biotech, which focuses on novel therapeutics for inflammatory diseases. Previous leadership roles include CEO of MycRx, a company developing cancer therapies, and CEO of Otifex Therapeutics, specializing in treatments for balance disorders. With expertise spanning various companies, including Athena Medicines, Aravax, and miReven, Christopher Wraight has a strong background in drug development and strategic advisory roles, supported by academic qualifications including a PhD in Biochemistry and an MBA in Technology Management.
This person is not in any teams
RAGE Biotech
RAGE Biotech Pty Ltd is a pharmaceutical start-up company developing novel therapeutics for patients with difficult-to-treat inflammatory disease. With our proprietary RNA therapeutics and peptide technologies, we are developing drugs targeting the Receptor for Advanced Glycation End-products (RAGE), a clinically important, pro-inflammatory ‘sensing’ receptor. Our most advanced programme is an inhaled drug for lung diseases where inflammation is a problem. RAGE Biotech was formed in 2020 with investments from IP Group, Monash Investment Holdings, the University of Western Australia and the Perron Instute.